Abstract:Abstract Learning Objectives After completing this course, the reader will be able to: Describe the presentation, differential diagnosis, and prognosis for patients with Ewing's sarcoma.Explain the principles of multidisciplinary management of Ewing's sarcoma.Discuss the late effects of the therapy for Ewing's sarcoma. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com Ewing's sarcoma is the second most frequent primary bone cancer, with approximately 225 new cases diagnosed each year in patients less than 20 years of age in North America. It is one of the pediatric small round blue cell tumors, characterized by strong membrane expression of CD99 in a chain-mail pattern and negativity for lymphoid (CD45), rhabdomyosarcoma (myogenin, desmin, actin) and neuroblastoma (neurofilament protein) markers. Pathognomonic translocations involving the ews gene on chromosome 22 and an ets-type gene, most commonly the fli1 gene on chromosome 11, are implicated in the great majority of cases. Clinical presentation is usually dominated by local bone pain and a mass. Imaging reveals a technetium pyrophosphate avid lesion that, on plain radiograph, is destructive, diaphyseal and classically causes layered periosteal calcification. Magnetic resonance best defines the extent of the lesion. Biopsy should be undertaken by an experienced orthopedic oncologist. Approximately three quarters of patients have initially localized disease. About two thirds survive disease-free. Management, preferably at a specialist center with a multi-disciplinary team, includes both local control—either surgery, radiation or a combination—and systemic chemotherapy. Chemotherapy includes cyclic combinations, incorporating vincristine, doxorubicin, cyclophosphamide, etoposide, ifosfamide and occasionally actinomycin D. Topotecan in combination with cyclophosphamide has shown preliminary activity. Patients with initially metastatic disease fare less well, with about one quarter surviving. Studies incorporating intensive therapy followed by stem cell infusion show no clear benefit. New approaches include anti-angiogenic therapy, particularly since vascular endothelial growth factor is an apparent downstream target of the ews-fli1 oncogene.

Central Nervous System Metastases in Pediatric Patients With Ewing Sarcoma

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience

Characterization of pediatric non-hematopoietic tumor metastases to the central nervous system: A single institution review

Ewing's Sarcoma of Maxillary Sinus

CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1/3 fusions

Ewing's Sarcoma of the Small Intestine with Liver Metastasis Mimicking Gastrointestinal Stromal Tumor

[Analysis of 41 cases of non-metastatic Ewing's sarcoma in children].

Ewing Sarcoma in the Pediatric Population: Predictors of Survival Within the United States

Ewing's Sarcoma Family of Tumors: Current Management

Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience

Primary Ewing sarcoma of the kidney: A series of four cases

Recurrent Intracranial Ewing Sarcoma

Ewing sarcoma with intra thoracic and multiple extra thoracic metastases in a young adult male: A case report

Case report: Pulmonary Ewing sarcoma disguised as non-small cell lung cancer

Ewing's sarcoma/primitive neuroectodermal tumor of the chest wall

Synchronous Low-Grade Central Osteosarcoma and Ewing Sarcoma: A Rare Case Report

Unusual “Mini-Rugby Ball” Pattern Solitary Lung Metastasis in Relapsed Ewing's Sarcoma

Some CNS sarcomas seen: A 22-year series

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

Sacral Ewing sarcoma with rib, lung, and multifocal skull metastases: A rare case report and review of treatments

Ewing Sarcoma of the Cervical Epidural Space Presenting with Tetraplegia: Case Report and Review of Literature